TBPH News and Press, Theravance Biopharma Inc. From 10/30/23

2023-10-30 18:50:40 ET More on Theravance Biopharma, Teva Pharmaceutical, etc. Viatris: Get Paid 5%, Before Growth Materializes Viatris' Survival Guide: Strategic Divestitures And Margins Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss...

Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023 PR Newswire DUBLIN , Oct. 19, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update...

2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-10-09 13:48:03 ET Summary Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been ...

2023-10-06 15:00:00 ET More on the stock market The U.S. Government Shutdown: Not A Crisis SPY Madness: 'Magnificent Seven' Stocks Up An Average 95% YTD While The Average Stock Is Down More Shades Of 2007 Buy-rated dividend stocks for volatility and high rate...

2023-10-05 05:30:00 ET More on Markets As 10-year Treasury yield pushes higher, Wolfe Research calls for 5% by year end Correction could be coming for mega caps - Wells Fargo Berenberg: Get defensive with healthcare, utilities and telecoms BlackRock is overwe...

2023-09-09 11:49:15 ET Summary Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's financials have shown improvement, with increased revenue and reduced R&D costs. Theravance's pr...

2023-09-08 10:12:51 ET Summary Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation for COPD treatment, but isn't yet a long-term compounder. Collaboration revenues and YUPELRI sales...

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders PR Newswire DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (N...

2023-08-16 03:00:21 ET Summary Baupost Group's 13F portfolio value decreased from $5.85B to $5.61B this quarter. The portfolio is heavily concentrated, with Liberty Global, Liberty Media Sirius XM, ViaSat, Alphabet, and Veritiv accounting for approximately 58% of the holdings. ...